Colman Kraff
Ophthalmology · Chicago, ILNPI 1912953712
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $19,250 of the $25,446 with a category attached, or 75.6%. Johnson & Johnson Surgical Vision, Inc. accounts for 62.8% of it on its own, with 26 other manufacturers making up the rest. Among ophthalmology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 204 payments — averaging $124.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$16K
- Rxsight Inc$6K
- Alcon$836
- Oyster Point Pharma, Inc.$290
- Novartis$276
- Glaukos Corporation$250
- plus $2K from 21 others
Across 51 payments — averaging $1159.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Johnson & Johnson Surgical Vision, Inc.$43K
- Glaukos Corporation$16K
What the payments were for
- Consulting fees$19,25076%
- Speaking & faculty fees$260%
- Food & beverage$5,93123%
- Other$2401%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 37 | $15,969 |
| Rxsight Inc | 28 | $5,806 |
| Alcon | 25 | $836 |
| Oyster Point Pharma, Inc. | 11 | $290 |
| Novartis | 16 | $276 |
| Glaukos Corporation | 9 | $250 |
| Carl Zeiss Meditec USA, Inc. | 1 | $240 |
| Bausch & Lomb Americas Inc. | 11 | $235 |
| Sun Pharmaceutical Industries Inc. | 10 | $213 |
| Kala Pharmaceuticals, Inc. | 7 | $164 |
| Harrow Eye, LLC | 6 | $163 |
| Aerie Pharmaceuticals, Inc. | 8 | $162 |
| Biotissue Holdings Inc. | 3 | $157 |
| AbbVie(2 entities) | 6 | $140 |
| Tarsus Pharmaceuticals, Inc. | 4 | $133 |
| Dompe US, Inc. | 3 | $69 |
| Eyevance Pharmaceuticals LLC | 5 | $63 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $56 |
| Shire North American Group Inc | 2 | $38 |
| Rayner Intraocular Lenses Limited | 1 | $36 |
| Sight Sciences, Inc. | 2 | $29 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| Ocular Therapeutix, Inc. | 1 | $22 |
| Apellis Pharmaceuticals, Inc. | 1 | $20 |
| Lensar, Inc. | 1 | $19 |
| Amgen | 1 | $19 |
| Coopervision Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iDesign Advanced Wavescan Studio$6,195
- Compact Intuitiv$5,605
- IFS ADVANCED FEMTOSEC LASER$5,605
- INTRALASE FS FEMTOSEC LASER$5,605
- RXSIGHT INJECTOR HANDPIECE$5,097
- RXSIGHT CONTACT LENS$5,097
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$5,097
- RXSIGHT INJECTOR CARTRIDGE$5,097
- LIGHT ADJUSTABLE LENS (LAL)$4,879
- IDESIGN RS$1,906
- STAR S4 IR$1,770
- CIRRUS 5000$240
- Wavelight Refractive Suite$236
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$218
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$142
- Prokera$124
- AmnioGraft$124
- CATALYS SYSTEM$105
How this compares
$25,446 in reported general payments places this provider in the 90th percentile of 773 ophthalmology providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 21 | $21,991 |
| XiidraLifitegrast | 15 | $13,158 |
| LumiganBimatoprost | 26 | $10,231 |
| Prednisolone Acetate | 142 | $7,407 |
| RocklatanNetarsudil Mesylat/Latanoprost | 12 | $4,805 |
| CombiganBrimonidine Tartrate/Timolol | 15 | $3,618 |
| Brimonidine Tartrate | 19 | $3,371 |
| MoxifloxacinMoxifloxacin Hcl | 149 | $2,935 |
| Latanoprost | 176 | $2,575 |
| Travoprost | 11 | $2,280 |
| Fluorometholone | 14 | $974 |
| Timolol Maleate | 45 | $339 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 28 | $309 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $140 | $35,84162 claims |
| Bausch & Lomb Americas Inc.Xiidra | $235 | $13,15815 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $162 | $4,80512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Chicago
- Seenu HariprasadChicago$2.3M
- Yannek LeidermanChicago$312K
- Asim FarooqChicago$270K
- Dilraj GrewalChicago$188K
- Ahmad ArefChicago$179K
- Robert SchroederChicago$153K
- Jennifer LimChicago$150K
- Surendra BastiChicago$126K
- Allen PuttermanChicago$94K
- Maria CortinaChicago$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.